Molecular markers in renal cell carcinoma -: Not quite ready for "prime time"

Molecular markers are becoming an increasingly important tool for diagnosing, staging, predicting recurrences of, and directing the treatment of multiple malignancies. However, variable techniques, variable antibodies, interobserver variability in the assessment of the markers, cost, and the lack of multi-institutional trials have limited the use of these markers in clinical practice.